AVTX
Price:
$10.13
Market Cap:
$106.00M
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phas...[Read more]
Industry
Biotechnology
IPO Date
2015-10-14
Stock Exchange
NASDAQ
Ticker
AVTX
According to Avalo Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 24.69M. This represents a change of -150.27% compared to the average of -49115592.68 of the last 4 quarters.
The mean historical Enterprise Value of Avalo Therapeutics, Inc. over the last ten years is 85.18M. The current 24.69M Enterprise Value has changed 2.80% with respect to the historical average. Over the past ten years (40 quarters), AVTX's Enterprise Value was at its highest in in the December 2017 quarter at 24.01B. The Enterprise Value was at its lowest in in the March 2024 quarter at -92972080.10.
Average
85.18M
Median
55.05M
Minimum
-8143266.98
Maximum
305.78M
Discovering the peaks and valleys of Avalo Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.03%
Maximum Annual Enterprise Value = 305.78M
Minimum Annual Increase = -161.36%
Minimum Annual Enterprise Value = -8143266.98
Year | Enterprise Value | Change |
---|---|---|
2023 | -4350684.30 | -108.11% |
2022 | 53.66M | -65.48% |
2021 | 155.44M | -11.42% |
2020 | 175.47M | -42.61% |
2019 | 305.78M | 161.24% |
2018 | 117.05M | 107.39% |
2017 | 56.44M | 1.03% |
2016 | 5.00M | -161.36% |
2015 | -8143266.98 | 79.83% |
2014 | -4528259.00 | 32.35% |
The current Enterprise Value of Avalo Therapeutics, Inc. (AVTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
68.25M
5-year avg
137.20M
10-year avg
85.18M
Avalo Therapeutics, Inc.’s Enterprise Value is less than AnaptysBio, Inc. (502.56M), less than Arcellx, Inc. (4.79B), less than Structure Therapeutics Inc. (1.75B), less than Aerovate Therapeutics, Inc. (46.23M), less than ALX Oncology Holdings Inc. (68.10M), less than Anebulo Pharmaceuticals, Inc. (36.46M), less than Acrivon Therapeutics, Inc. Common Stock (163.47M), less than PMV Pharmaceuticals, Inc. (47.77M), less than Molecular Partners AG (130.63M), less than Mineralys Therapeutics, Inc. (523.81M), greater than Alzamend Neuro, Inc. (4.67M), greater than Virax Biolabs Group Limited (5.36M), greater than Kiromic BioPharma, Inc. (13.48M), less than Benitec Biopharma Inc. (175.91M), less than Century Therapeutics, Inc. (104.89M), less than Edgewise Therapeutics, Inc. (3.01B), less than C4 Therapeutics, Inc. (307.45M), less than Cullinan Oncology, Inc. (630.54M), less than Miromatrix Medical Inc. (90.06M), less than ZIVO Bioscience, Inc. (73.95M), greater than Bionomics Limited (-2112255.00),
Company | Enterprise Value | Market cap |
---|---|---|
502.56M | $677.65M | |
4.79B | $4.89B | |
1.75B | $1.91B | |
46.23M | $76.81M | |
68.10M | $74.37M | |
36.46M | $37.86M | |
163.47M | $202.87M | |
47.77M | $83.31M | |
130.63M | $216.81M | |
523.81M | $621.09M | |
4.67M | $5.86M | |
5.36M | $8.73M | |
13.48M | $1.69M | |
175.91M | $243.54M | |
104.89M | $102.89M | |
3.01B | $3.05B | |
307.45M | $300.00M | |
630.54M | $730.17M | |
90.06M | $92.95M | |
73.95M | $74.08M | |
-2112255.00 | $5.75M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Avalo Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Avalo Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Avalo Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Avalo Therapeutics, Inc. (AVTX)?
What is the 3-year average Enterprise Value for Avalo Therapeutics, Inc. (AVTX)?
What is the 5-year average Enterprise Value for Avalo Therapeutics, Inc. (AVTX)?
How does the current Enterprise Value for Avalo Therapeutics, Inc. (AVTX) compare to its historical average?